Sulfin and sulfonamidino derivatives of cephalosporins.

ABSTRACT

This disclosure is directed to derivatives of 6-amino penicillanic and 7-amino cephalosporanic acids having the following structural formulas:   WHEREIN R, R1-R4 and n are defined herein.

United States Patent [191 Nudelman et al.

[451 July 8,1975

[ SULFIN AND SULFONAMIDINO DERIVATIVES OF CEPHALOSPORINS.

[75] Inventors: Abraham Nudelman, Montgomery; Ronald J. McCaully, Chester, both of Pa.

[73] Assignee: American Home Products Corporation, New York, NY.

[22] Filed: May '7, 1973 [21] App]. N0.: 357,761

[52] U.S. Cl 260/243 C; 424/246; 260/239.1; 424/271 [51] Int. Cl. C07D 501/16 [58] Field of Search 260/243 C [56] References Cited UNITED STATES PATENTS 3,660,379 5/1972 Murimoto et al 260/2391 3,748,323 7/1973 Hamanakai 260/2391 Primary Examiner-Nicholas S. Rizzo Attorney, Agent, or FirmStephen Venetianer [57] ABSTRACT This disclosure is directed to derivatives of 6-amin0 penicillanic and 7-amino cephalosporanic acids having the following structural formulas:

wherein R, R R and n are defined herein.

5 Claims, No Drawings SlULFIN AND SULFONAMIDINO DERIVATIVES OF CEPHALOSPORINS.

FIELD OF THE INVENTION This invention relates to derivatives of 6-amino penicillanic (-APA) and 7-amino cephalosporanic acids (7-ACA). More particularly, this invention relates to sulfinamidino and sulfonamidino derivatives of 6-APA and 7-ACA.

SUMMARY OF THE INVENTION This invention relates to the following novel derivatives of 6-APA and 7-ACA represented by the following structural formulas:

DESCRIPTION OF THE INVENTION As used herein the term (lower)alkyl means a straight or branch chain hydrocarbon radical having C C carbons. Illustrative of (lower)alkyl is methyl, ethyl, isopropyl. butyl, sec-butyl, hexyl, etc. The term (lower)alkylaryl is exemplified by tolyl and xylyl. The term aryl includes phenyl and naphthyl. The term aryloxy includes phenoxy and naphthoxy. The term ar(lower)alkyl means monocyclic and bicyclic carbo cyclic lower alkyl radicals exemplified by benzyl, ,B-phenylethyl, a-phenylpropyl, a-phenylethyl and a-naphthylethyl.

The preferred compounds of the present invention have the following structural formula:

wherein R is phenyl, benzyl or tolyl, R is phenyl, methyl or ethyl or p-tolylsulfonyl, R is hydrogen or trialkylammonium cation, R is hydrogen or (lower)alkanoyloxy and R is hydrogen or trialkylammonium cation.

The compounds of this present invention can be prepared in the following manner:

1 N-R (1H1; w Q R-S-X NH n r--n tertiary amine compound 1 -Q- R T x NH2[:::T///

( l N CH 33 a V co R tertiary amine compound II wherein: X=chlorine or bromine Compounds of Formula III wherein n is 0 may be prepared by the following method established in the prior art. E. S. Levchenko and L. V. Selezenko Z. Org. Khim (USSR), 2, 92 (I966) 1 l 2R -NX 9 aa-s-x X Compounds of Formula Ill wherein n is or 1 may be prepared by the followingmethod established in the prior art. 1

E. S. Levchenko, N. Ya Derkach and A. V. Kivsanov,

Z. Obchei. Khim, 31 1971 (1961) Compounds of Formula 111 wherein n is 1 may be prepared by the following method established in the prior art.

E. V. Johnson, C. C. Bacon and C. R. Johnson, J. Am. cl1 s;) 93, 5306 1971) As will be understood by those skilled in the art, the compounds of Formula 1 and 11 may be utilized in their acid form or in the form of their therapeutically active salts thereof, e .g., the sodium or potassium salts, or in the form of the pharmaceutically acceptable salts prepared by the reaction of the penicillin or cephalosporin compounds with an amine, a trialkylamine, or diamine base, e.g., triethylamine, procaine or various N-N'- disubstituted alkylene diamines, such as N,N-dibenzylethylene-diamine, etc-Additionally, the compounds of Formula 1 and 11 may be utilized in their hydrated form.

The new compounds of the series defined above show desirable broad spectrum anti-bacterial activity and are useful as therapeutic agents for poultry and mammals in the treatment of infectious diseases caused by gram-positive and gram-negative bacteria by either parenteral or oral administration, particularly strains of Bacillus subtilis, Staphylococcus aureusy Salmonella paratyphi, and Klebsiella pneumoniae. 0

As will also beunder stood 'by those skilled in the art, the compounds of the invention may be utilized in suitable dosage forms, including solutions, suspensions, tablets, capsules, and the like.

The following examples are illustrative "of the invention.

EXAMPLE 1] 5-Chloro-5-p-toly1-N-p-tolysulfonylsulfilimine This compound was obtained in 90 percent yield following theprocedure of Levchenko and co-workers referred to previously. When recrystallized from dichloromethane it showed a melting point of 141.5-142.5, nmr (DCCl ppm 8 2.53 (s; 6), 7.3 (m, 4), 8 (m, 4).

Anal. Calcd for C H ClNO S C, 51.30; H, 4.27. Found: C, 51.21; H, 4.25.

EXAMPLE 2 6-[ N p-Tolylsulfonyl )-p-toluenesulfinamidino]- penicillanic acid triethylamine salt To an ice cold solution of saminopenicillanic acid (2.16 g, 10' mole) and triethylamine (2.5 g) in ml of dichloromethane, a solution of 5-chloro"-5-p-tolyl-N-,

p-tolyls'ulfohylsuliilimineiobtained in'Example 1 (3.3 g, 10 mole) in 25 ml of dichloromethane is added. The solution is stirred at ice temperature for 1 hour and at room temperature for an additional hour. The solution is then washed with ice coild water, dried and flash evaporated at 35. The residual oil is mixed with ether to give 6-[N'-(p-to1ylsulfo'r1yl)-ptoluenesulfinamidino] penicillanic acid triethylamines'alt as a whitesolid, that decomposes above 150, nmr (DMSO-D ppm 6 1.2 (t, 9), 1.50 (s, 3), 1.57 (s, 3), 2.35 (s, 6), 3.07 (q, 6), 4.20 (s, 1), 5.02 (q,2,.lj.,,, 3cps; A8 0.1 ppm), 7.1-7.9 (m, 8). 1 A

Anal. Calcd for C ,,H, N,O S C, 55.23; H, 6.62; N,

9.20. Found: C, 55.24; H, 6.68; N, 9.08.

EXAMPLE 3 1 EXAMPLE 4 6+(N-Methylbenzenesulfonamidino)penicillanic acid To a solution of Nmethyl-benzenesulfonimidoyl chloride (10 moles), in 50 ml of dichloromethane at -,C, a solution of 6-aminopenicillanic acid (2.16 g, 10 mole) and triethylamine (3.5g) in 50 ml of dichloromethane at 70?C is added. Thesolution is allowed to reaclyroom; temperature slowly and then stirred for 1 hour and washed with water. The organic phase is dried and concentrated at 35? to a smallyolume, which is then added dropwise to vigorously stirred pentane.

.The solid precipitateQis filtered and dri ed, to give .the

title compound as an amorphous solid, which decomposes-when heated, nmr (DMSO-D ),ppm 8 1.4, (s, 3), 1.55'(s, 3 ,.3.3'(,,s, 3), 4.2 (s, 1 5.3-5.6 (m, 2), 7.6 -,8.1 "1,51,

Anal. Calcd for c,,u,,N,,o', s,=fc,g1s.76; 11,, 5.18 1 1, 11.37; s, 17.32. Found: C, 49.29; H, 5.44; N, 10.89; S, 16.84.

" EXAMPLE 5 ;7-(N'-Phenyl oz-toluenesulfonimidamido) cephalosporanic acid, dihydr ate The above compound is prepared by the same procedure as that describedin Example 4 from 7-aminocephalosporanic acid (1.35 g, 5 mmoles) and N-phenyl-bengylsulfonimidoyl chloride (1.35 g, 5 mmoles). Theqobtained product decomposes when heated, nmr (.DCCl,-,) ppm 5 2.05 (s, 3), 3.3-3.6 (m, 2), 4.5-5.2 (m, 6), 7-7.8 (m, 10).

Anal. Calcd for C H N O S ZH Q: C, 51.38; H,

Found: C, 50.97;, H, 4.45;N, 7.61.

EXAMPLE 6 7-( N-Ethyl-a-toluenesulfonimidamido )cephalosporanic acid The title compound was prepared by the same procedure as that described in Example 4 from 7-aminocephalosporanic acid (1.35 g, 5 mmoles) and N-ethylbenzylsulfonimidoyl chloride (1.09 g, 5 mmoles). The N-ethylbenzylsulfonylimidoyl chloride was prepared by Johnsons procedure [1. Am. Chem. Soc. 93. 5306 (1971)] from N-ethylbenzylsulfinamide and chlorine. The obtained product decomposed upon heating.

Anal. Calcd for C H N O S z C, 50.32; H, 5.11.

Found: C, 50.06; H. 5.50.

The compounds of formula I and ll of this invention have been found to possess antibacterial activity. Antibacterial screening is carried out by an agar serial dilution technique. Distilled water is used as a vehicle. The stock solution is prepared at l0,000p.g./ml. of substance in the vehicle. Twofold dilutions are made with sterile water. One ml. quantitites of each dilution are incorporated into 9 ml. seed agar in sterile petrie dishes. The hardened surface is inoculated with test organisms and incubated 18 hours at 35C. The end point is reported as a minimal inhibitory concentration (MIC) expressed in ,ug./ml.; the least amount of test substance that will completely inhibit the test organism. The compound of Example 6 when tested against Staphylococcus aureus 65381 and Staphylococcus aureus Smith produced a MIC value in each case of 1.94 pug/ml and when tested against Bacillus .s'u/nillus produced a MIC value of 0.244 ug/ml.

What is claimed is:

1. A compound selected from the group consisting of:

wherein R is selected from the group consisting of (lower)alkyl, tolyl, xylyl, phenyl. naphthyl. benzyl. B-phenylethyl, a-phenylpropyl, a-phenylethyl, a-naphthylethyl, and phenoxy(lower)all yl and naphthoxy(- lower)alltyl; R is selected from the group consisting of (lower)all yl, phenyl. naphthyl, phenyl sulfonyl and naphthyl sulfonyl; R is selected from the group consisting of hydrogen, hydroxyl, (lower)all anoyloxy; benzoyloxy,; R is selected from the group consisting of hydrogen or a pharmaceutically acceptable cation and n is l or 0.

Z. A compound according to claim 1 wherein the compound is 7-[N"(p-Tolysulfonyll-ptoluenesulfinamidino] cephalosporanic acid. triethylamine salt.

3. A compound according to claim 11 wherein the compound is 7-(N'-Phenyl-atoluenesulfonimidamido)cephalosporanic acid. dihy drate.

4. A compound according to claim 1 wherein the compound is 7-(N-Ethyl-atoluenesulfonimidamido)cephalosporanic acid.

5. A compound according to claim 11 wherein R is se lected from the group consisting of phenyl, benzyl and tolyl, R is selected from the group consisting of phenyl, methyl, ethyl and p-tolylsulfonyl. R is hydrogen or loweralkanoyloxy and R is hydrogen or trialkylammonium cation. 

1. A COPOUND SELECTED FROM THE GROUP CONSISTING OF:
 2. A compound according to claim 1 wherein the compound is 7-(N''-(p-Tolysulfonyl)-p-toluenesulfinamidino) cephalosporanic acid, triethylamine salt.
 3. A compound according to claim 1 wherein the compound is 7-(N''-Phenyl- Alpha -toluenesulfonimidamido)cephalosporanic acid, dihydrate.
 4. A compound according to claim 1 wherein the compound is 7-(N''-Ethyl- Alpha -toluenesulfonimidamido)cephalosporanic acid.
 5. A compound according to claim 1 wherein R is selected from the group consisting of phenyl, benzyl and tolyl, R1 is selected from the group consisting of phenyl, methyl, ethyl and p-tolylsulfonyl, R3 is hydrogen or loweralkanoyloxy and R4 is hydrogen or trialkylammonium cation. 